Editorial Board
Mingyan Xu
CEO & Founder of HaploX · China
Editorial leadership for Journal of Current Scientific Research ISSN 2766-8681
Research interests
- Biotechnology
- &Nbsp; Dna Sequencing
- &Nbsp;Genomics
- &Nbsp; Synthetic Biology
- &Nbsp; Cancer Biology
- &Nbsp;Radiopharmaceuticals
Biography
- CEO&Founder of Haplox Biotechnology (Shenzhen) co., LtD Aug. 2014-present
- Staff Scientist at Cambrian Genomics Inc. USA Jan. 2013-July 2014
- DNA laser printing technology
- Lead to a revolution of synthetic biology by providing multiplex parallel-synthesized gene size DNA oligonucleotides for lower cost, higher accuracy, and higher throughput.
- Leveraged Next-Generation Sequencing technology to invent the first DNA recoverable sequencer in the world for DNA Laser Printing.
- Research Assistant at Univ. of New Mexico
- Aug. 2008-July 2013‚• Led the ‘Polony Sequencing and the $1,000 Genome’ project funded by NIH to Jeremy S. Edwards ($3 Million). Invented Rolony (Rolling Circle amplified Colony) sequencing by ligation (Collaborated with George M. Church Lab at Harvard Medical School) and by synthesis (SBL and SBS) on Polonator G.007 and MINI-20/GeneReader (Qiagen)
- Developed NGS applications on Preimplantation Genetic Diagnosis and Screening (PGD/PGS), tumor early diagnosis, monitoring and drug-resistant evaluation.
- Invented Haplotype-Resolved Sequencing technology to directly measure haplotype information unprecedentedly.
- Firstly developed Dual Primer emulsion PCR (DPePCR) technology for Polony Sequencing.
- Extensive experience on MiSeq, Hiseq2000/2500 (Illumina), Polonator G.007, Ion PGM/Proton, MINI-20/GeneReader Next-generation Sequencers.
- Extensive experience with different NGS sample preparation methods and protocols. Familiar with Bowtie/Bowtie2, SAMtools, CLCBio, Golden Helix, etc. Open source and commercial NGS data analysis tools. 2 Quality Controller at Beijing Shihong Pharmaceuticals Sept. 2005-June 2008
- Quality control of a serial of pharmaceuticals, i.e., [ 99mTc]-MIBI, [ 99mTc] technetepyrophosphate, [ 99mTc]-Pentetate, [ 99mTc]- MAA, etc.
- Synthesized more than 500GRAM of hexakis-2-methoxyisobutylisonitrile (MIBI), which can supply the China market for at least 10 years.
- Extensive experience on manufactory pipeline of radiopharmaceuticals, including organic synthesis, kit recipe development, and sample sterilized distribution, cryodesiccation, radio labeling, quality control, etc.
Considering JCSR for your work?
This journal is guided by Mingyan Xu (CEO & Founder of HaploX) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.